Hetero-bivalent agents targeting FAP and PSMA

[1]  K. Kopka,et al.  Investigation of Tumor Cells and Receptor-Ligand Simulation Models for the Development of PET Imaging Probes Targeting PSMA and GRPR and a Possible Crosstalk between the Two Receptors. , 2022, Molecular pharmaceutics.

[2]  Jiawei Zhong,et al.  18F- or 177Lu-labeled bivalent ligand of fibroblast activation protein with high tumor uptake and retention , 2022, European Journal of Nuclear Medicine and Molecular Imaging.

[3]  D. Neri,et al.  A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake , 2022, The Journal of Nuclear Medicine.

[4]  K. Rahbar,et al.  Prostate-specific membrane antigen and fibroblast activation protein distribution in prostate cancer: preliminary data on immunohistochemistry and PET imaging , 2021, Annals of Nuclear Medicine.

[5]  L. de Geus-Oei,et al.  Molecular Targeted Positron Emission Tomography Imaging and Radionuclide Therapy of Pancreatic Ductal Adenocarcinoma , 2021, Cancers.

[6]  J. Czernin,et al.  Correlation of 68Ga-FAPi-46 PET Biodistribution with FAP Expression by Immunohistochemistry in Patients with Solid Cancers: Interim Analysis of a Prospective Translational Exploratory Study , 2021, The Journal of Nuclear Medicine.

[7]  A. Afshar-Oromieh,et al.  New Frontiers in Cancer Imaging and Therapy Based on Radiolabeled Fibroblast Activation Protein Inhibitors: A Rational Review and Current Progress , 2021, Pharmaceuticals.

[8]  Mengxin Xu,et al.  Albumin Binder–Conjugated Fibroblast Activation Protein Inhibitor Radiopharmaceuticals for Cancer Therapy , 2021, The Journal of Nuclear Medicine.

[9]  Zhide Guo,et al.  Synthesis, Preclinical Evaluation, and a Pilot Clinical PET Imaging Study of 68Ga-Labeled FAPI Dimer , 2021, The Journal of Nuclear Medicine.

[10]  O. Sanli,et al.  Fibroblast Activation Protein-Targeted PET Imaging of Metastatic Castration-Resistant Prostate Cancer Compared With 68Ga-PSMA and 18F-FDG PET/CT. , 2021, Clinical nuclear medicine.

[11]  M. Gleave,et al.  High fibroblast-activation-protein expression in castration-resistant prostate cancer supports the use of FAPI-molecular theranostics , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[12]  R. Baum,et al.  Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using 177Lu-FAP-2286: First-in-Humans Results , 2021, The Journal of Nuclear Medicine.

[13]  C. V. van Herpen,et al.  PSMA radioligand therapy for solid tumors other than prostate cancer: background, opportunities, challenges, and first clinical reports , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[14]  M. Pomper,et al.  Imaging of Fibroblast Activation Protein in Cancer Xenografts Using Novel (4-Quinolinoyl)-glycyl-2-cyanopyrrolidine-Based Small Molecules. , 2021, Journal of medicinal chemistry.

[15]  D. Jäger,et al.  [153Sm]Samarium-labeled FAPI-46 radioligand therapy in a patient with lung metastases of a sarcoma , 2021, European Journal of Nuclear Medicine and Molecular Imaging.

[16]  Charles J. Smith,et al.  Development of Heterobivalent Theranostic Probes Having High Affinity/Selectivity for the GRPR/PSMA. , 2021, Journal of Medicinal Chemistry.

[17]  M. Stockler,et al.  [177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial , 2021, The Lancet.

[18]  J. López,et al.  Altered Tissue and Plasma Levels of Fibroblast Activation Protein-α (FAP) in Renal Tumours , 2020, Cancers.

[19]  R. Kumar,et al.  Differentiating benign and malignant pancreatic masses: Ga-68 PSMA PET/CT as a new diagnostic avenue , 2020, European Radiology.

[20]  M. Yadav,et al.  A theranostic approach of [68Ga]Ga-DOTA.SA.FAPi PET/CT-guided [177Lu]Lu-DOTA.SA.FAPi radionuclide therapy in an end-stage breast cancer patient: new frontier in targeted radionuclide therapy , 2020, European Journal of Nuclear Medicine and Molecular Imaging.

[21]  P. Nelson,et al.  Imaging Fibroblast Activation Protein Alpha Improves Diagnosis of Metastatic Prostate Cancer with Positron Emission Tomography , 2020, Clinical Cancer Research.

[22]  Lei Zheng,et al.  Preclinical mouse models for immunotherapeutic and non-immunotherapeutic drug development for pancreatic ductal adenocarcinoma , 2020, Annals of pancreatic cancer.

[23]  L. Weiner,et al.  The role of fibroblast activation protein in health and malignancy , 2020, Cancer and Metastasis Reviews.

[24]  I. Badiola,et al.  Altered expression of fibroblast activation protein-α (FAP) in colorectal adenoma-carcinoma sequence and in lymph node and liver metastases , 2020, Aging.

[25]  B. McNeil,et al.  Radiotheranostics: a roadmap for future development. , 2020, The Lancet. Oncology.

[26]  I. Nabipour,et al.  Precision Medicine Approach in Prostate Cancer. , 2020, Current pharmaceutical design.

[27]  D. Murphy,et al.  Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer , 2020, Nature Reviews Urology.

[28]  P. Timpson,et al.  CAF Subpopulations: A New Reservoir of Stromal Targets in Pancreatic Cancer. , 2019, Trends in cancer.

[29]  T. Watabe,et al.  Theranostics Targeting Fibroblast Activation Protein in the Tumor Stroma: 64Cu- and 225Ac-Labeled FAPI-04 in Pancreatic Cancer Xenograft Mouse Models , 2019, The Journal of Nuclear Medicine.

[30]  Thomas Lindner,et al.  Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention , 2019, The Journal of Nuclear Medicine.

[31]  W. Oyen,et al.  Prostate-specific Membrane Antigen Heterogeneity and DNA Repair Defects in Prostate Cancer , 2019, European urology.

[32]  M. Pomper,et al.  177Lu-labeled low-molecular-weight agents for PSMA-targeted radiopharmaceutical therapy , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[33]  M. Röhrich,et al.  IDH-wildtype glioblastomas and grade III/IV IDH-mutant gliomas show elevated tracer uptake in fibroblast activation protein–specific PET/CT , 2019, European Journal of Nuclear Medicine and Molecular Imaging.

[34]  M. Pomper,et al.  Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT , 2019, Annals of Nuclear Medicine.

[35]  H. Kauczor,et al.  68Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer , 2019, The Journal of Nuclear Medicine.

[36]  M. Pomper,et al.  Improved identification of patients with oligometastatic clear cell renal cell carcinoma with PSMA-targeted 18F-DCFPyL PET/CT , 2019, European Urology Supplements.

[37]  T. Powles,et al.  Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal‐Cell Carcinoma , 2019, The New England journal of medicine.

[38]  Thomas Lindner,et al.  Development of Quinoline-Based Theranostic Ligands for the Targeting of Fibroblast Activation Protein , 2018, The Journal of Nuclear Medicine.

[39]  E. Puré,et al.  Pro-tumorigenic roles of fibroblast activation protein in cancer: back to the basics , 2018, Oncogene.

[40]  K. Pienta,et al.  Low-Level Endogenous PSMA Expression in Nonprostatic Tumor Xenografts Is Sufficient for In Vivo Tumor Targeting and Imaging , 2018, The Journal of Nuclear Medicine.

[41]  G. Kristiansen,et al.  Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role , 2018, The Journal of urology.

[42]  E. Wardelmann,et al.  Neovascular Prostate-Specific Membrane Antigen Expression Is Associated with Improved Overall Survival under Palliative Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma , 2017, BioMed research international.

[43]  E. Pirog,et al.  Prostate-specific Membrane Antigen (PSMA) Expression in the Neovasculature of Gynecologic Malignancies: Implications for PSMA-targeted Therapy , 2017, Applied immunohistochemistry & molecular morphology : AIMM.

[44]  F. Oliver,et al.  Vasculogenic mimicry signaling revisited: focus on non-vascular VE-cadherin , 2017, Molecular Cancer.

[45]  R. Pulido,et al.  The Expression of Fibroblast Activation Protein in Clear Cell Renal Cell Carcinomas Is Associated with Synchronous Lymph Node Metastases , 2016, PloS one.

[46]  R. Kalluri.  The biology and function of fibroblasts in cancer , 2016, Nature Reviews Cancer.

[47]  Z. Zemanová,et al.  Fibroblast activation protein alpha is expressed by transformed and stromal cells and is associated with mesenchymal features in glioblastoma , 2016, Tumor Biology.

[48]  R. Pulido,et al.  Fibroblast activation protein predicts prognosis in clear cell renal cell carcinoma. , 2016, Human pathology.

[49]  Yuan-feng Yang,et al.  The Presence of Vascular Mimicry Predicts High Risk of Clear Cell Renal Cell Carcinoma after Radical Nephrectomy. , 2016, The Journal of urology.

[50]  H. Hong,et al.  Noninvasive brain cancer imaging with a bispecific antibody fragment, generated via click chemistry , 2015, Proceedings of the National Academy of Sciences.

[51]  C. Sheridan.  Amgen's bispecific antibody puffs across finish line , 2015, Nature Biotechnology.

[52]  A. Lambeir,et al.  Extended structure-activity relationship and pharmacokinetic investigation of (4-quinolinoyl)glycyl-2-cyanopyrrolidine inhibitors of fibroblast activation protein (FAP). , 2014, Journal of medicinal chemistry.

[53]  M. Pomper,et al.  Heterobivalent Agents Targeting PSMA and Integrin-αvβ3 , 2014, Bioconjugate chemistry.

[54]  J. Lai,et al.  Quantitation of fibroblast activation protein (FAP)-specific protease activity in mouse, baboon and human fluids and organs , 2013, FEBS open bio.

[55]  L. Shapiro,et al.  Prostate specific membrane antigen produces pro-angiogenic laminin peptides downstream of matrix metalloprotease-2 , 2013, Angiogenesis.

[56]  J. Isaacs,et al.  Rationale Behind Targeting Fibroblast Activation Protein–Expressing Carcinoma-Associated Fibroblasts as a Novel Chemotherapeutic Strategy , 2012, Molecular Cancer Therapeutics.

[57]  M. Pomper,et al.  Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen. , 2011, Angewandte Chemie.

[58]  L. Weiner,et al.  Fibroblast Activation Protein and Its Relationship to Clinical Outcome in Pancreatic Adenocarcinoma , 2008, Pancreas.

[59]  J. Neale,et al.  NAAG peptidase inhibition reduces locomotor activity and some stereotypes in the PCP model of schizophrenia via group II mGluR , 2004, Journal of neurochemistry.

[60]  V. Reuter,et al.  Five different anti-prostate-specific membrane antigen (PSMA) antibodies confirm PSMA expression in tumor-associated neovasculature. , 1999, Cancer research.

[61]  L. Old,et al.  Cell surface glycoprotein of reactive stromal fibroblasts as a potential antibody target in human epithelial cancers. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[62]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.

[63]  C. Cordon-Cardo,et al.  Prostate-specific membrane antigen expression in normal and malignant human tissues. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.